AbbVie (ABBV)

AbbVie wins FDA approval for Rinvoq in giant cell arteritis after strong Phase 3 results and a 57.2% year-over-year sales increase in Q1.

Shares of AbbVie (ABBV) have gained more than 12% in the past week. But now they are overbought and may reverse.

U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this week.

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for.

Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising drug and healthcare costs.

Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments.

Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

U.S. stock futures are down in early-morning trade on Monday, after ending the previous week on a high note, with back-to-back sessions of strong rallies.

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results tomorrow morning. Here’s what investors should know.

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings tomorrow morning. Here’s what you need to know.

US Markets Rise as Big Tech Shines, Trade Tensions Remain a Concern

Despite some near-term pressures in aesthetics and legacy products, the overall outlook for 2025 remains positive.

AbbVie stock climbs after Q1 earnings beat and 2025 EPS forecast raise; strong growth in immunology and neuroscience portfolios led the results.

Wall Street's three-day rally came to a pause on Friday, with major indices hovering near the flatline by midday in New York as caution returned amid mixed signals on U.S.-China trade relations.

Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.

AbbVie is well-positioned for industry-leading growth, as Skyrizi and Rinvoq sales outperform, driving system-wide growth alongside a diversified portfolio.